DPH: Zika Information for Healthcare Providers

Zika Information for Healthcare Providers

{Albopictus picture}

Zika virus is a single-stranded RNA virus of the Flaviviridae family, genus Flavivirus. Zika virus is transmitted to humans primarily through the bite of an infected Aedes species mosquito, but perinatal, in utero, sexual and possible transfusion transmission events have also been reported. Most people infected with Zika virus are asymptomatic. Characteristic clinical findings are acute onset of fever with maculopapular rash that is usually itchy, arthralgia, or conjunctivitis. Other commonly reported symptoms include myalgia and headache. Clinical illness is usually mild with symptoms lasting for several days to a week. Severe disease requiring hospitalization is uncommon and case fatality is low. However, there have been cases of Guillain-Barré syndrome. Zika virus is a cause of microcephaly and possibly other congenital neurologic abnormalities. Please see information below for up-to-date recommendations for testing and management of infants and women of childbearing age, pregnant women, and their partners.

State Specific Information


All testing performed by the State Public Health Laboratory, must be approved by the Connecticut Department of Public Health, Epidemiology and Emerging Infections Program (EEIP). Providers may fax the Zika Virus Report Form to 860-509-7910. An epidemiologist will review and contact you by the next business day.

Testing Performed to Identify Zika Virus Infection

Test Criteria and Information

National Information

Centers for Disease Control and Prevention (CDC)

Testing of infants, placenta, or products of conception is performed at the CDC and must be approved by both the DPH and CDC. To discuss testing of these samples, contact the EEIP at 860-509-7994.

Zika Virus Information for Healthcare Providers


This page includes information about Zika virus and sexual transmission, and information for obstetrical and pediatric healthcare providers, as well as the following: 


Guidelines for Testing and Care of Patients with Potential Exposure to Zika Virus


For Obstetrical Healthcare Providers

For Neonatal and Pediatric Healthcare Providers


Zika Virus Testing - Interpreting Results




Food and Drug Administration (FDA)

To contact the Epidemiology and Emerging Infections Program, please call 860-509-7994.

Content Last Modified on 10/5/2016 8:44:09 AM